From synapse to nucleus: Novel targets for treating depression

被引:83
作者
Covington, Herbert E., III [1 ]
Vialou, Vincent [1 ]
Nestler, Eric J. [1 ]
机构
[1] Mt Sinai Sch Med, Fishberg Dept Neurosci, New York, NY 10029 USA
关键词
Depression; Antidepressant; SSRI; MAOI; Stress; Mouse; Rat; Clinical; Epigenetics; Glutamate; Neurotrophin; Steroid receptor; Intracellular signaling; BDNF; Ghrelin; ESTROGEN-RECEPTOR-BETA; TREATMENT-RESISTANT DEPRESSION; MESSENGER-RNA EXPRESSION; FIBROBLAST-GROWTH-FACTOR; DEEP BRAIN-STIMULATION; CENTRAL-NERVOUS-SYSTEM; D-ASPARTATE ANTAGONIST; ASTERISK-D COHORT; MAJOR DEPRESSION; MOOD DISORDERS;
D O I
10.1016/j.neuropharm.2009.12.004
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The need for newer compounds to treat depression is an ever-growing concern due to the enormous societal and financial ramifications of this disorder. Here, we review some of the candidate systems that could potentially be involved in depression, or an inherent resistance to depression termed resilience, and the numerous protein targets for these systems. A substantial body of literature provides strong evidence that neurotrophic factors, glutamate receptors, hypothalamic feeding peptides, nuclear hormone receptors, and epigenetic mechanisms, among others, will make for interesting targets when examining depressive behavior or resilience in preclinical models, and eventually clinical trials. Although some of these targets for depression already appear promising, new waves of more selective compounds for any molecular system should promote a better understanding of this complex disease and perhaps improved treatments. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:683 / 693
页数:11
相关论文
共 161 条
[1]   Estrogen deficiency in severe postpartum depression:: Successful treatment with sublingual physiologic 17β-estradiol:: A preliminary study [J].
Ahokas, A ;
Kaukoranta, J ;
Wahlbeck, K ;
Aito, M .
JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (05) :332-336
[2]   Anxiolytic-like effects through a GLUKS kainate receptor mechanism [J].
Alt, Andrew ;
Weiss, Brianne ;
Ornstein, Paul L. ;
Gleason, Scott D. ;
Bleakman, David ;
Stratford, Robert E., Jr. ;
Witkin, Jeffrey M. .
NEUROPHARMACOLOGY, 2007, 52 (07) :1482-1487
[3]   Anxiolytic-like effect of the selective Neuropeptide YY2 receptor antagonist BIIE0246 in the elevated plus-maze [J].
Bacchi, Fabrizio ;
Mathe, Aleksander A. ;
Jimenez, Patricia ;
Stasi, Luigi ;
Arban, Roberto ;
Gerrard, Philip ;
Caberlotto, Laura .
PEPTIDES, 2006, 27 (12) :3202-3207
[4]   Chronic antidepressant treatments increase basic fibroblast growth factor and fibroblast growth factor-binding protein in neurons [J].
Bachis, Alessia ;
Mallei, Alessandra ;
Cruz, Maria Idalia ;
Wellstein, Anton ;
Mocchetti, Italo .
NEUROPHARMACOLOGY, 2008, 55 (07) :1114-1120
[5]   Antidepressant effects of ketamine in depressed patients [J].
Berman, RM ;
Cappiello, A ;
Anand, A ;
Oren, DA ;
Heninger, GR ;
Charney, DS ;
Krystal, JH .
BIOLOGICAL PSYCHIATRY, 2000, 47 (04) :351-354
[6]   Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress [J].
Berton, O ;
McClung, CA ;
DiLeone, RJ ;
Krishnan, V ;
Renthal, W ;
Russo, SJ ;
Graham, D ;
Tsankova, NM ;
Bolanos, CA ;
Rios, M ;
Monteggia, LM ;
Self, DW ;
Nestler, EJ .
SCIENCE, 2006, 311 (5762) :864-868
[7]   New approaches to antidepressant drug discovery: beyond monoamines [J].
Berton, O ;
Nestler, EJ .
NATURE REVIEWS NEUROSCIENCE, 2006, 7 (02) :137-151
[8]   Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression [J].
Bespalov, Anton Y. ;
van Gaalen, Marcel M. ;
Sukhotina, Irina A. ;
Wicke, Karsten ;
Mezler, Mario ;
Schoemaker, Hans ;
Gross, Gerhard .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 592 (1-3) :96-102
[9]  
Bleakman D., 2007, CNS & Neurological Disorders-Drug Targets, V6, P117, DOI 10.2174/187152707780363258
[10]  
Bolaños CA, 2003, J NEUROSCI, V23, P7569